ArticleContraception: X2020

A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen.

Thomas Kimble et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.